Corona Remedies Share Price | Corona Remedies Stock Screener
CORONA
Pharmaceuticals
Share Price NSE
₹1777.30
▼
-8.60 (-0.48%)
Share Price BSE
₹1779.10
▼
-4.05 (-0.23%)
As of May 15, 2026, the Corona Remedies share price (NSE: CORONA) is ₹1,777.30 on NSE and ₹1,779.10 on BSE, down 0.48% from the previous close, with shares trading between ₹1,755.00 and ₹1,849.90, and a 52-week range of ₹1,347.70–₹1,785.90.
Check CORONA yearly price range for the annual price range and momentum.
Use the Corona Remedies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Corona Remedies Market Cap
₹10,114.66 Cr.
CORONA P/E Ratio (TTM)
53.75
Corona Remedies P/B Ratio
13.32
EPS (TTM)
₹30.27
Dividend Yield
-
Debt to Equity
0.23
CORONA 52 Week High
₹1785.90
Corona Remedies 52 Week Low
₹1347.70
Operating Margin
18.00%
Profit Margin
12.57%
CORONA Revenue (TTM)
₹358.00
EBITDA
₹66.00
Net Income
₹45.00
Total Assets
₹1,205.00
Total Equity
₹747.00
Corona Remedies Share Price Chart
Screen Corona Remedies share price with an interactive chart. Analyse CORONA price trends and volatility across different timeframes.
Corona Remedies Company Profile - Fundamental Screener
Screen Corona Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for CORONA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE02ZQ01018
Corona Remedies Balance Sheet Screener
Screen CORONA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Assets | ||||
| Total Assets | 1,205 | 930 | 831 | 595 |
| Current Assets | 348 | 339 | 290 | 292 |
| Fixed Assets | 723 | 370 | 384 | 185 |
| Liabilities | ||||
| Total Liabilities | 0 | 0 | 0 | 0 |
| Current Liabilities | 97 | 84 | 126 | 49 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||
| Total Equity | 747 | 606 | 480 | 409 |
| Share Capital | 61 | 61 | 61 | 61 |
| Reserves & Surplus | 686 | 545 | 419 | 347 |
Corona Remedies Income Statement Screener - Profit & Revenue Analysis
Screen Corona Remedies income statement and profit fundamentals.
Analyze CORONA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Corona Remedies share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Revenue | 358 | 295 | 349 | 364 | 345 | 293 | 316 | 299 |
| Expenses | 291 | 240 | 277 | 283 | 278 | 242 | 247 | 228 |
| EBITDA | 66 | 56 | 72 | 81 | 66 | 51 | 69 | 70 |
| Operating Profit % | 18.00% | 18.00% | 20.00% | 22.00% | 19.00% | 17.00% | 21.00% | 23.00% |
| Depreciation | 10 | 10 | 9 | 9 | 9 | 8 | 9 | 10 |
| Interest | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 2 |
| Profit Before Tax | 55 | 44 | 61 | 70 | 55 | 39 | 57 | 58 |
| Tax | 9 | 12 | 15 | 18 | 14 | 9 | 14 | 13 |
| Net Profit | 45 | 32 | 46 | 52 | 41 | 30 | 43 | 45 |
| EPS | 7.41 | 5.16 | 7.55 | 8.55 | 6.75 | 4.90 | 7.03 | 7.35 |
Corona Remedies Cash Flow Screener - Liquidity Fundamentals
Screen CORONA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March |
|---|---|---|---|
| Operating Activities | 191 | 157 | 103 |
| Investing Activities | -84 | -267 | -50 |
| Financing Activities | -107 | 99 | -45 |
| Net Cash Flow | 0 | -11 | 8 |
Corona Remedies Shareholding Pattern Screener
See Corona Remedies shareholding pattern with promoter, FII, and DII holdings.
Check Corona Remedies promoter holding and ownership changes for CORONA on TickJournal.
| Item | 2026-Mar | 2025-Apr | 2025-Dec |
|---|---|---|---|
| Promoter Holding | 69.00% | 72.50% | 69.00% |
| FII Holding | 2.25% | 0.00% | 1.84% |
| DII Holding | 7.02% | 0.00% | 6.76% |
| Govt Holding | 0.00% | 0.00% | 0.00% |
| Public Holding | 0.77% | 0.00% | 1.36% |
| Other Holding | 20.97% | 27.50% | 21.05% |
| Shareholder Count | 19,609 | 9 | 9 |
Corona Remedies Share Dividend Screener - Share Yield Analysis
Check Corona Remedies dividend history with payout and yield data.
View Corona Remedies dividend details including ex-dates and amounts for CORONA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹7.31 | 0.47% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Corona Remedies Stock Index Membership
See which indices include Corona Remedies stock.
Check CORONA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Corona Remedies Market Events Screener - Corporate Actions
Get Corona Remedies corporate actions including splits, bonuses, and buybacks.
Check Corona Remedies stock events that may affect CORONA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-11 | 2026-05-11 | Quarterly Result Announcement | NA | 1.36% |
| 2026-02-02 | 2026-02-02 | Quarterly Result Announcement | NA | 3.06% |
| 2026-01-02 | 2026-01-02 | Quarterly Result Announcement | NA | 4.10% |
Corona Remedies Competitors Screener - Peer Comparison
Screen CORONA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 443,037 | 40.44 | 54,729 | 9.71% | 10,980 | 62.53 |
| Divis Laboratories | 177,652 | 71.15 | 9,712 | 18.67% | 2,191 | 66.51 |
| Torrent Pharmaceuticals | 147,461 | 65.25 | 11,539 | 6.99% | 1,911 | 58.68 |
| Dr Reddys Laboratories | 106,985 | 19.19 | 33,741 | 16.73% | 5,725 | 48.03 |
| Cipla | 105,949 | 23.02 | 28,410 | 7.12% | 5,291 | 49.42 |
| Lupin | 102,314 | 19.18 | 27,488 | 19.98% | 5,345 | 41.00 |
| Mankind Pharma | 98,446 | 54.43 | 12,744 | 20.90% | 2,007 | 65.09 |
| Zydus Life Science | 93,947 | 18.63 | 23,511 | 18.55% | 4,615 | 52.94 |
| Aurobindo Pharma | 86,539 | 24.81 | 32,346 | 9.43% | 3,484 | 70.74 |
| Laurus Labs | 68,114 | 77.00 | 6,813 | 21.03% | 884 | 75.68 |
Corona Remedies Company Announcements - News Screener
Screen CORONA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Annual Secretarial Compliance Report For The Financial Year Ended March 31 2026 | - | |
| Annual Secretarial Compliance Report For The Financial Year Ended March 31 2026 | - | |
| Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - | |
| Announcement under Regulation 30 (LODR)-Newspaper Publication | - | |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-15 | Record Date For The Purpose Of Final Dividend For The F.Y. 2025-26 Is June 19 2026 | - |
| 2026-05-15 | Corporate Action-Board approves Dividend | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-15 | Financial Results For The Fourth Quarter And Year Ended March 31 2026 | - |
| 2026-05-15 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-04-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-04-30 | Board Meeting Intimation for Consideration And Approval Of Audited Financial Results On Standalone And Consolidated Basis For The Fourth Quarter And Year Ended On March 31 2026 | - |
| 2026-04-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-30 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-30 | Closure of Trading Window | - |